XXXX Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression.

@entity1 @entity4562 @entity5 @entity470 @entity12379 @entity1149 @entity1442 @entity669 @entity204 @entity3866
@entity1149 ( @entity1149 ) is the leading cause of @entity204 from @entity5 for both @entity1 and @entity1 . Chemotherapy is the mainstay of treatment in @entity1442 , but is only marginally effective. In about 30% of @entity1 with advanced @entity1149 in East Asia and in 10-15% in Western countries, @entity470 ( @entity470 ) mutations are found. In this population, first-line treatment with the @entity669 kinase inhibitors (TKIs) @entity3866 , @entity4562 , or @entity12379 is recommended. The treatment beyond progression is less well-defined. In this paper, we present three @entity1 , @entity470 mutation positive, with local progression after an initial treatment with TKI. These @entity1 were treated with local radiotherapy. TKI was temporarily stopped and restarted after radiotherapy. We give an overview of the literature and discuss the different treatment options in case of progression after TKI: TKI continuation with or without chemotherapy, TKI continuation with local therapy, alternative dosing or switch to next-generation TKI or combination therapy. There are different options for treatment beyond progression in @entity470 mutation positive metastatic @entity1149 , but the optimal strategy is still to be defined. Further research on this topic is ongoing.
